secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gamida Cell Ltd. (—)
CIK:        0001600847
Form:       8-K
Filed at:   2023-03-27T23:59:59+00:00
Accession:  0001213900-23-022951
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gamida Cell FY2022 net loss $79.4M; cuts 17% workforce; cash runway to Q3 2023
------------------------------------------------------------------------------

- Net loss $79.4M in FY2022 ($89.8M in 2021); cash $64.7M at year-end.
- Cuts workforce 17% (~$1.1M severance) to extend cash runway through Q3 2023; discontinues preclinical NK pipeline.
- Omidubicel PDUFA date May 1, 2023; exploring strategic partnerships; plans to launch at 10-15 transplant centers.
- Board chair change: Shawn Cline Tomasello elected chair; two other directors resigned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600847/000121390023022951/0001213900-23-022951-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600847/000121390023022951/ea175734-8k_gamida.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-022951

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer